Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
10.9758/cpn.2021.19.1.174
- Author:
Domenico De BERARDIS
1
;
Gabriella RAPINI
;
Luigi OLIVIERI
;
Agostina GIARDINI
;
Ida De LAURETIS
;
Nicola SERRONI
;
Laura ORSOLINI
;
Michele FORNARO
;
Felice IASEVOLI
;
Sabatino TROTTA
;
Paolo COTTURA
;
Federica VELLANTE
;
Marco ALESSANDRINI
;
Massimo Di GIANNANTONIO
Author Information
1. National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini,” Teramo, Italy
- Publication Type:Case Report
- From:Clinical Psychopharmacology and Neuroscience
2021;19(1):174-178
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
